Medical Devices DECODED
Previous edition: 27 Mar 2024
Share article
Get the full version straight to your inbox.
Exclusive access to our best-in-class data & intelligence
Subscribe now
FDA issues clearance to Calyxo's redesigned CVAC System
This new system has already been used in over 50 procedures, receiving positive feedback from both patients and physicians.
The US Food and Drug Administration (FDA) has approved Calyxo’s redesigned CVAC System, a medical device aimed at enhancing the treatment of kidney stones through a minimally invasive approach.
This new system has already been used in more than 50 procedures, receiving positive feedback from both patients and physicians.
The utilisation of the original CVAC Aspiration System in steerable ureteroscopic renal evacuation (SURE) has proven effective in treating over 1,500 patients in the US.
This method has showcased notable improvements in clinical outcomes, boasting a volumetric stone clearance rate of 97%.
Clinical study data from treated patients indicates a high success rate in avoiding secondary or more invasive procedures.
The redesigned system is the result of two years of real-world application and feedback. It is claimed to be a unique complete stone clearance solution that integrates ureteroscopy, laser lithotripsy, irrigation, and aspiration.
Calyxo president and CEO Joe Catanese said: “We are excited to introduce the first complete stone clearance solution, which we believe will revolutionise how kidney stones are treated.
“By enabling the physician to continuously clear stone dust through passive aspiration during laser lithotripsy and then remove residual fragments through active vacuum aspiration, the SURE procedure with our new CVAC system leads to highly effective stone clearance.
“We are gratified with the overwhelmingly positive feedback from urologists thus far and we are looking forward to making the technology more widely available in the coming months.”
The system is said to offer direct visualisation, dedicated irrigation channels, and a large aspiration lumen for the effective and efficient removal of kidney stones.
Last year, Calyxo closed $50m in a Series D financing round to support a broad launch of CVAC kidney stone treatments.
The round was led by Avidity Partners with significant participation from existing investors Questa Capital and CRG.
Latest news
Cleerly touts new data for AI cardiovascular software
The AI-QCT ISCHEMIA software uses AI to analyse atherosclerosis and blood vessel shapes from CCTA images.
Explainer: IVF access in Alabama - what comes next?
On 16 February the Alabama supreme court ruled that embryos used by IVF facilities constitute living children in a decision that has sent the state-wide industry into crisis.
Implantica gears up for FDA approval of acid reflux device
Implantica has submitted the first module of the PMA application for RefluxStop, with subsequent modules planned for submission in the next six months.
Avicenna.AI wins two FDA clearances for AI tools in CT scans
The FDA clears two algorithms for incidental pulmonary embolism detection and stroke severity assessment.
Endostart bags FDA 510(k) clearance for magnetic colonoscopy device
According to GlobalData’s Medical Intelligence Centre, the global colonoscope market is forecast to grow beyond $4.4bn by the end of 2030.
Wipro GE Healthcare plans $959m investment in India to boost production
Wipro GE plans to produce PET CT Discovery IQ diagnostic scan devices for export to 15 countries.
In our previous edition
Medical Devices Decoded
Abbott's insertable cardiac monitor receives CE Mark
26 Mar 2024
Medical Devices Decoded
FDA issues 510(k) clearance for RedDrop Dx's blood collection device
25 Mar 2024
Medical Devices Decoded
USPTO backs Medtronic in patent infringement case against Axonics
22 Mar 2024
Newsletters in other sectors
Aerospace, Defence & Security
Automotive
Banking & Payments
Construction
Medical Devices
Travel and Tourism
Search companies, themes, reports, as well as actionable data & insights spanning 22 global industries
Access more premium companies when you subscribe to Explorer